Endothelial cell function and thrombosis

Bailliere's Best Practice and Research in Clinical Haematology

Volumn 12, Issue 3, 1999, Pages 329-341

  Pearson, Jeremy D ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Endothelium; Nitric oxide; Plasminogen activator; Prostacyclin; Thrombin; Thrombomodulin; Von Willebrand Factor

Indexed keywords

ANTITHROMBIN; ANTITHROMBOCYTIC AGENT; CELL RECEPTOR; NITRIC OXIDE; NUCLEOTIDASE; PROSTACYCLIN; THROMBIN; THROMBIN RECEPTOR; THROMBOMODULIN; THROMBOPLASTIN; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

BLOOD CLOTTING; CELL SURFACE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; THROMBIN TIME; THROMBOCYTE ADHESION; THROMBOSIS; VASCULAR ENDOTHELIUM;

EID: 0033506297     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1053/beha.1999.0028     Document Type: Article

References (96)

1. Moncada S. Biological importance of prostacyclin. British Journal of Pharmacology. 76:1982;3-31.
2. Furchgott R F, Zawadski J V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 288:1980;373-376.
3. Moncada S, Palmer R MJ, Higgs E A. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacological Reviews. 43:1991;109-142.
4. Radomski M W, Palmer R MJ, Moncada S. Comparative pharmacology of endothelium-dependent relaxing factor, nitric oxide and prostacyclin in platelets. British Journal of Pharmacology. 92:1987;181-187.
5. Radomski M WI, Palmer R MJ, Moncada S. The role of nitric oxide and CGMP in platelet adhesion to vascular endothelium. Biochemical and Biophysical Research Communications. 148:1987;1482-1489.
6. Rees D D, Palmer R MJ, Moncada S. Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proceedings of the National Academy of Sciences of the USA. 86:1989;3375-3378.
7. Blair I A, Barrow S F, Waddell K A. Prostacyclin is not a circulating hormone in man. Prostaglandins. 23:1982;577-589.
8. Freedman J E, Sauter R, Battinelli E M. Deficient platelet-derived nitric oxide and enhanced hemostasis in mice lacking the NOSIII gene. Circulation Research. 84:1999;1416-1421.
9. Nakayama T, Soma M, Rahmutula D. Nonsense mutation of prostacyclin synthase gene in a family. Lancet. 349:1997;1887-1888.
10. Mülsch A, Busse R, Bassenge E. Nitric oxide synthesis in endothelial cytosol: evidence for a calcium-dependent and a calcium-independent mechanism. Naunyn-Schmiedeberg's Archives of Pharmacology. 340:1989;767-770.
11. Carter T D, Pearson J D. Regulation of prostacyclin synthesis in endothelial cells. News in Physiological Sciences. 7:1992;64-69.
12. 2release but has no effect on von Willebrand Factor secretion or E-selectin expression. FEBS Letters. 388:1996;180-184.
13. Takahashi M, Ishida T, Traub O. Mechanotransduction in endothelial cells: temporal signaling events in response to shear stress. Journal of Vascular Research. 34:1997;212-219.
14. Rubanyi G M, Romero J C, Vanhoutte P M. Flow-induced release of endothelium-derived relaxing factor. American Journal of Physiology. 250:1986;H145-H149.
15. Ayajiki K, Kindermann M, Hecker M. Intracellular pH and tyrosine phosphorylation but not calcium determine shear stress-induced nitric oxide production in native endothelial cells. Circulation Research. 78:1996;750-758.
16. Fulton D, Gratton J-P, McCabe T J. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature. 399:1999;597-601.
17. Dimmeler S, Fleming I, Fisslthaler B. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature. 399:1999;601-605.
18. Davies M J. A macro and micro view of coronary vascular insult in ischemic heart disease. Circulation. 82:1990;38-46.
19. Ludmer P L, Selwyn A P, Shook T L. Paradoxical vasoconstriction by acetylcholine in atherosclerotic coronary arteries. New England Journal of Medicine. 315:1986;1046-1051.
20. Zeiher A M, Drexler H, Wollschläger H, Tust H. Modulation of coronary vasomotor tone in humans. Progressive endothelial dysfunction with different early stages of coronary atherosclerosis. Circulation. 83:1991;391-401.
21. Maxwell A J, Tsao P S, Cooke J P. Modulation of the nitric oxide synthase pathway in atherosclerosis. Experimental Physiology. 83:1998;573-584.
22. Miyazaki H, Matsuoka H, Cooke J P. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation. 99:1999;1141-1146.
23. Fitzgerald G A, Smith B, Pedersen A K, Brash A R. Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. New England Journal of Medicine. 310:1984;1065-1068.
24. Marcus A J, Weksler B B, Jaffe E A, Broekman M J. Synthesis of prostacyclin from platelet-derived endoperoxides by cultured human endothelial cells. Journal of Clinical Investigation. 66:1980;979-986.
25. Barry O P, Pratico D, Lawson J A, FitzGerald G A. Transcellular activation of platelets and endothelial cells by bioactive lipids in platelet microparticles. Journal of Clinical Investigation. 99:1997;2118-2127.
26. Noris M, Benigni A, Siegler R. Renal prostacyclin biosynthesis is reduced in children with hemolytic-uremic syndrome in the context of systemic platelet activation. American Journal of Kidney Diseases. 20:1992;144-149.
27. McIntyre T M, Zimmerman G A, Satoh K, Prescott S M. Human endothelial cells synthesize both platelet-activating factor and prostacyclin in response to histamine, bradykinin and adenosine triphosphate. Journal of Clinical Investigation. 76:1985;275-280.
28. Toothill V J, van Mourik J A, Hiewenhuis H K. Characterization of the enhanced adhesion of neutrophil leukocytes to thrombin-stimulated endothelial cells. Journal of Immunology. 145:1990;283-296.
29. Zimmerman G A, McIntyre T M, Mehra M, Prescott S M. Endothelial cell-associated platelet-activating factor: a novel mechanism for signalling intercellular adhesion. Journal of Cell Biology. 110:1990;529-540.
30. Gawaz M, Neumann F J, Dickfeld T. Vitronectin receptor mediates platelet adhesion to the luminal aspect of endothelial cells - implications for reperfusion in acute myocardial infarction. Circulation. 96:1997;1809-1818.
31. Celi A, Lorenzet R, Furie B, Furie B C. Platelet-leukocyte-endothelial cell interaction on the blood vessel wall. Seminars in Hematology. 34:1997;327-335.
32. Bahra P, Nash G B. Sparsely adherent platelets support capture and immobilization of flowing neutrophils. Journal of Laboratory and Clinical Medicine. 132:1998;223-228.
33. Slupsky J R, Kalbas M, Willuweit A. Activated platelets induce tissue factor expression on human umbilical vein endothelial cells by ligation of CD40. Thrombosis and Haemostasis. 80:1998;1008-1014.
34. Henn V, Slupsky J R, Grafe M. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 391:1998;591-594.
35. Pearson J D, Slakey L L, Gordon J L. Stimulation of prostaglandin production through purinoceptors on cultured porcine endothelial cells. Biochemical Journal. 214:1983;273-276.
36. Zimmerman H, Pearson J D. Extracellular metabolism of nucleotides and adenosine in the cardiovascular system. Burnstock G, Dobson J G, Liang B T, Linden J. Cardiovascular Biology of Purines. 1998;342-358 Kluwer, Boston.
37. Marcus A J, Safier L B, Hajjar K. Inhibition of platelet function by an aspirin-insensitive endothelial cell ADPase. Journal of Clinical Investigation. 88:1991;1690-1696.
38. Enjyoji K, Sevigny J, Lin Y. Targeted disruption of CD39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation. Nature Medicine. 5:1999;1010-1017.
39. Bowie E JW, Solberg L A, Fass D N. Transplantation of normal bone marrow into a pig with severe von Willebrand's disease. Journal of Clinical Investigation. 78:1986;26-30.
40. Wagner D D. Cell biology of von Willebrand factor. Annual Review of Cell Biology. 6:1990;217-246.
41. Roth G J. Developing relationships: arterial platelet adhesion, glycoprotein Ib, and leucine-rich glycoproteins. Blood. 77:1991;5-19.
42. Mannucci P M. Von Willebrand factor - a marker of endothelial damage? Arteriosclerosis, Thrombosis and Vascular Biology. 18:1998;1359-1362.
43. Pottinger B E, Read R C, Paleology E M, Pearson J D. Von Willebrand factor is an acute phase reactant in man. Thrombosis Research. 53:1989;387-394.
44. Paleolog E M, Crossman D C, McVey J H, Pearson J D. Differential regulation by cytokines of constitutive and stimulated secretion of vWf from endothelial cells. Blood. 75:1990;688-695.
45. Pearson J D. Vessel wall interactions regulating thrombosis. British Medical Bulletin. 50:1994;776-788.
46. Savage C OS, Pottinger B E, Gaskin G. Vascular damage in Wegener's granulomatosis and microscopic polyarteritis: presence of anti-endothelial cell antibodies and their relation to anti-neutrophil cytoplasm antibodies. Clinical and Experimental Immunology. 85:1991;14-19.
47. Van Mourik J A, Boertjes R, Huisveld I A. Von Willebrand factor propeptide in vascular disorders: a tool to distinguish between acute and chronic endothelial cell perturbation. Blood. 94:1999;179-185.
48. Moake J L. Studies on the pathophysiology of thrombotic thrombocytopenic purpura. Seminars in Hematology. 34:1997;83-89.
49. Furlan M, Robles G, Galbusera M. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. New England Journal of Medicine. 339:1998;1578-1584.
50. Mannucci P M, Lombardi R, Lattuada R. Supranormal von Willebrand factor multimers in scleroderma. Blood. 74:1989;978-983.
51. Vu T-K H, Hung D T, Wheaton V I, Coughlin S R. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell. 64:1991;1057-1068.
52. Hollenberg M D. Protease-mediated signalling: new paradigms for cell regulation and drug development. Trends in Pharmacological Sciences. 17:1996;3-6.
53. Schmidt V A, Nierman W C, Maglott D R. The human poteinase-activated receptor-3 (PAR-3) gene - identification within a PAR gene cluster and characterization in vascular endothelial cells and platelets. Journal of Biological Chemistry. 273:1998;15061-15068.
54. Molino M, Woolkalis M J, Reavey-Cantwell J. Endothelial cell thrombin receptors and PAR-2 - two protease-activated receptors located in a single cellular environment. Journal of Biological Chemistry. 272:1997;11133-11141.
55. Langer F, Morys-Wortmann C, Kusters B, Storck J. Endothelial protease-activated receptor-2 induces Tissue Factor expression and von Willebrand factor release. British Journal of Haematology. 105:1999;542-550.
56. Marcum J A, Kenny J B, Rosenberg R D. Acceleration of thrombin-antithrombin complex formation in rat hindquarters via heparin-like molecules bound to the endothelium. Journal of Clinical Investigation. 74:1984;341-350.
57. Esmon C T. Thrombomodulin as model of molecular mechanisms that modulate protease specificity and function at the vessel surface. FASEB Journal. 9:1995;946-955.
58. Weiler-Guettler H, Christie P D, Beeler D L. A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state. Journal of Clinical Investigation. 101:1998;1983-1991.
59. Fukudome K, Esmon C T. Identification, cloning and regulation of a novel endothelial cell protein C/activated protein C receptor. Journal of Biological Chemistry. 269:1994;26486-26491.
60. Laszik Z, Mitro A, Taylor F B. Human protein C receptor is resent primarily on endothelium of large blood vessels - implications for the control of the Protein C pathway. Circulation. 96:1997;3633-3640.
61. Nawroth P, Stern D. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. Journal of Experimental Medicine. 163:1986;740-745.
62. Ogawa S, Gerlach H, Esposito C. Hypoxia modulates the barrier and coagulant functions of cultured bovine endothelium. Journal of Clinical Investigation. 85:1990;1090-1098.
63. Gosling M, Golledge J, Turner R J, Powell J T. Arterial flow conditions downregulate thrombomodulin on spahenous vein endothelium. Circulation. 99:1999;1047-1053.
64. Amano K, Takevama M, Inaba H. Fluctuations in plasma levels of thrombomodulin in patients with DIC. Thrombosis and Haemostasis. 68:1992;404-406.
65. Wada H, Ohiwa M, Kaneko T. Plasma thrombomodulin as a marker of vascular disorders in thrombotic thrombocytopenic pupura and disseminated intravascular coagulation. American Journal of Hematology. 39:1992;20-24.
66. Karmochkine M, Boffa M C, Piette J C. Increase in plasma thrombomodulin in lupus erythematosus with antiphospholipid antibodies. Blood. 79:1992;837-838.
67. Takahashi H I, Ito S, Hanano M. Circulating thrombomodulin as a novel endothelial cell marker: comparison of its behavior with von Willebrand factor and tissue-type plasminogen activator. American Journal of Hematology. 41:1992;32-39.
68. Yamazaki M, Asakura H, Sato T. Changes in plasma levels of thrombomodulin during haemodialysis. Blood Coagulation and Fibrinolysis. 3:1992;113-117.
69. Salomaa V, Matei C, Aleksic N. Soluble thrombomodulin as a predictor of incident coronary heart disease and symptomless carotid artery atherosclerosis in the Atherosclerosis Risk in Communities (ARIC) study: a case-cohort study. Lancet. 353:1999;1729-1734.
70. Blann A D, de Romeuf C, Mazurier C, McCollum C N. Circulating von Willebrand factor antigen II in atherosclerosis: a comparison with von Willebrand factor and soluble thrombomodulin. Blood Coagulation & Fibrinolysis. 9:1998;261-266.
71. Esmon C T, Gu J M, Xu J. Regulation and functions of the protein C anticoagulant pathway. Haematologica. 84:1999;363-368.
72. Maynard J R, Dreyer B E, Stemerman M B, Pitlick F A. Tissue factor coagulant activity of cultured endothelial and smooth muscle cells and fibroblasts. Blood. 50:1977;387-396.
73. Davie D W, Fujikawa K, Kisiel W. The coagulation cascade: initiation, maintenance and regulation. Biochemistry. 30:1991;10363-10370.
74. Lyberg T, Galdal K S, Evensen S A, Prydz H. Cellular cooperation in endothelial thromboplastin synthesis. British Journal of Haematology. 53:1983;85-95.
75. Bevilacqua M P, Pober J S, Majeau G R. Interleukin 1 induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. Journal of Experimental Medicine. 160:1984;618-623.
76. Brox J H, Østerud B, Bjørklid E, Fenton J W. Production and availability of thromboplastin in endothelial cells: the effects of thrombin, endotoxin and platelets. British Journal of Haematology. 57:1984;239-246.
77. Crossman D C, Carr D P, Tuddenham E GD. The control of tissue factor mRNA in human endothelial cells in response to endotoxin or phorbol ester. Journal of Biological Chemistry. 265:1990;9782-9787.
78. Camera M, Giesen P LA, Fallon J. Cooperation between VEGF and TNF-α is necessary for exposure of active tissue factor on the surface of human endothelial cells. Arteriosclerosis, Thrombosis and Vascular Biology. 19:1999;531-537.
79. Holzmuller H, Moll T, Hofer-Warbinek R. A transcriptional repressor of the tissue factor gene in endothelial cells. Arteriosclerosis, Thrombosis and Vascular Biology. 19:1999;1804-1811.
80. Etingin D R, Silverstein R L, Friedman H M, Hajjar D P. Viral activation of the coagulation cascade: molecular interactions at the surface of infected endothelial cells. Cell. 61:1990;657-662.
81. Pearson J D. The control of production and release of haemostatic factors in the endothelial cell. Baillière's Clinical Haematology. 6:1993;629-651.
82. Bajaj M S, Kuppuswamy M N, Saito H. Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: evidence that endothelium is the principal site of its synthesis. Proceedings of the National Academy of Sciences of the USA. 87:1990;8869-8873.
83. Sandset P M. Tissue factor pathway inhibitor (TFPI) - an update. Haemostasis. 26:1996;154-165.
84. Lupu C, Goodwin C A, Westmuckett A D. Tissue Factor pathway inhibitor in endothelial cells colocalizes with glycolipid microdomains/caveolae. Arteriosclerosis, Thrombosis and Vascular Biology. 17:1997;2964-2974.
85. Warr T A, Rao L VM, Rapaport S I. Disseminated intravascular coagulation in rabbits induced by administration of endotoxin or tissue factor: effect of anti-tissue factor antibodies and measurement of plasma extrinsic pathway inhibitor. Blood. 75:1990;1481-1489.
86. Emeis J J. The control of tPA and PAI-1 release from the vessel wall. Vascular Medicine Review. 6:1995;153-166.
87. Emeis J J, van den Eijnden-Schrauwen Y, van den Hoogen C M. An endothelial storage granule for tissue-type plasminogen activator. Journal of Cell Biology. 139:1997;245-256.
88. Hajjar K A. Cellular receptors in the regulation of plasmin generation. Thrombosis and Haemostasis. 74:1995;294-301.
89. Schleef R R, Bevilacqua M P, Sawdey M. Interleukin 1 and tumor necrosis factor activation of vascular endothelium: effects on plasminogen activator inhibitor and tissue-type plasminogen activator. Journal of Biological Chemistry. 263:1988;5797-5803.
90. Colucci M, Paramo J A, Collen D. Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation. Journal of Clinical Investigation. 75:1985;818-824.
91. Van der Poll T, Levi M, Buller H R. Fibrinolytic response to tumour necrosis factor in healthy subjects. Journal of Experimental Medicine. 174:1991;729-732.
92. Pepper M S. Manipulating angiogenesis. Arteriosclerosis, Thrombosis and Vascular Biology. 17:1997;605-619.
93. Koolwijk P, van Erck M GM, de Vree W JA. Cooperative effect of TNF, bFGF and VEGF on the formation of tubular structures of human endothelial cells in a fibrin matrix. Role of urokinase activity. Journal of Cell Biology. 132:1996;1177-1188.
94. Yamagishi S, Fujimori H, Yonekura H. Advanced glycation endproducts inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells. Diabetologia. 41:1998;1435-1441.
95. Allison B A, Nilsson L, Karpe F, Hamsten A, Eriksson P. Effects of native, triglyceride-enriched and oxidatively modified LDL on plasminogen activator inhibitor-1 expression in human endothelial cells. Arteriosclerosis, Thrombosis and Vascular Biology. 19:1999;1354-1360.
96. Marx N, Bourcier T, Sukhova G K. PPARγ activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression. Arteriosclerosis, Thrombosis and Vascular Biology. 19:1999;546-551.